# The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

> **NCT03542110** · PHASE4 · TERMINATED · sponsor: **Minneapolis Heart Institute Foundation** · enrollment: 46 (actual)

## Conditions studied

- Saphenous Vein Graft Atherosclerosis

## Interventions

- **DRUG:** Alirocumab 150 MG/ML subcutaneous injection
- **DRUG:** Matching Placebo subcutaneous injection

## Key facts

- **NCT ID:** NCT03542110
- **Lead sponsor:** Minneapolis Heart Institute Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-04
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-07-31
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Withdrawal of medication and funding support by Sponsor
- **Last updated:** 2021-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03542110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03542110, "The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT03542110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*